Article

Biden Cancer Initiative Announces Oncology Clinical Trial Information Commons

In an effort to allow patients to know their clinical trial options, the Biden Cancer Initiative has announced that 9 healthcare innovators are coming together to form the Oncology Clinical Trial Information Commons.

In an effort to allow patients to know their clinical trial options, the Biden Cancer Initiative has announced that 9 healthcare innovators are coming together to form the Oncology Clinical Trial Information Commons. The shared platform, which will be used to sore information on clinical trials and be accessed for patient matching and other data mining, will employ a single set of terms ad rules and a user-friendly interface for companies to enter and update information, such as patient selection criteria, trial locations, and patient participation requirements.

Founding members of the collaboration include BreastCancerTrials.org, Cancer Commons, Ciitizen, EmergingMed, GenomOncology, Genospace/Sarag Cannon Research Center, IBM Watson Health, Massive Bio, and Syapse.

Read the full release.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
David Awad, PharmD, BCOP
Andrew Kuykendall, MD, Moffitt Cancer Center
Merrill H. Stewart, MD
Dr Margrit Wiesendanger
David Awad, PharmD, BCOP
H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview
Dr Margrit Wiesendanger
Ibrahim Aldoss, MD, associate professor, City of Hope
Manmeet Ahluwalia, MD, MBA, FASCO, chief of medical oncology, chief scientific officer, and deputy director of the Miami Cancer Institute of Baptist Health South Florida
Cathy Eng, MD, FACP, FASCO
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo